Equity Overview
Price & Market Data
Price: $0.97
Daily Change: -$0.0169 / 1.75%
Range: $0.96 - $1.07
Market Cap: $23,228,900
Volume: 118,589
Performance Metrics
1 Week: -3.01%
1 Month: -9.09%
3 Months: -11.50%
6 Months: -9.09%
1 Year: -25.93%
YTD: -16.67%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.